NanoMedSyn was born from the fundamental research of its biologist and chemist founders who discovered a breakthrough technology for drug delivery to the lysosomal cell compartment leading to potentiation of therapeutics. This technology, validated at the preclinical level, has a wide range of applications in the fields of oncology, immunity, inflammation or metabolism.
Our researchers have years of experience in the field of nanotechnologies.
The AMFA is a patented synthetic derivative designed for the targeting of the mannose 6-phosphate receptor.
NanoMedSyn is growing up and has already recruted new doctors to cope with its needs.